Low Carbon Development Strategy on Land Use Sector in Ciliwung Middle-stream Watershed

The second (2nd) and third (3rd) segment of Ciliwung middle-stream watershed land use have changed drastically over the past two decades. The second (2nd) and third (3rd) segment of Ciliwung middle-stream watershed land use have changed drastically over the past two decades. This paper analyses the land use change from 1989-2012 and its impact on decreasing carbon stock or increasing CO2 eq emission, as well as to establish projected Reference Level (RL) to 2020. Best RL projection was used to establish the Low Carbon Development Strategy (LCDS) in both segments. The land use changing from 1989-2012 indicated a reduction of green space area by 2,575.57 ha whereas the non-green space area increased by 2,575.57 ha. These changes decreases the carbon stock by 26,900 ton C and released CO eq emission by about 98,723 ton CO2eq. Population growth, demand on land and land constraints were found to be the driving factors of land use changes in this area. Reference Level 2020 was established based on business as usual (BAU) and forward looking (FL) scenarios. The projection showed that FL was the best scenario which estimated carbon storage at 217,610 ton C in 2020. Low carbon development strategy directed to the area of green space added up to 20% carbon storage through the implementation of the strategy based on green space and non-green space which covered the areas from protection, supervision, extension or awareness and law enforcement

Leucine Supplementation Does Not Improve Muscle Recovery from Resistance Exercise in Young Adults: A Randomized, Double-Blinded, Crossover Study

International Journal of Exercise Science 14(2): 486-497, 2021. This study aimed to investigate the effects of free leucine supplementation on muscle recovery from resistance exercise (RE) in young adults. Fourteen untrained subjects (23.9 ± 3.6 years old) underwent RE sessions (leg press and hack squat: three sets of 8-12 reps at 70% 1RM) supplemented with leucine (LEU: two daily doses of 3g) or a placebo (PLA), separated by a seven-day washout period. Following each occasion, participants were evaluated in three subsequent days (24h, 48h, and 72h) for muscle recovery via a repetition-to-failure test. The following markers were assessed: repetition performance, perceived exertion, lactate, creatine kinase, muscle soreness (DOMS), testosterone, and cortisol. No significant difference was observed between LEU and PLA conditions (p \u3e 0.05). Number of repetitions performed in the repetition-to-failure tests, perceived exertion, cortisol, and testosterone:cortisol ratio did not change over time (p \u3e 0.05). Creatine kinase increased immediately after exercise, at 24h, and 48h, and was attenuated at 72h post-exercise, while testosterone, lactate, and DOMS increased at 24h post-exercise (p \u3c 0.05) and remained elevated up to 72h. All outcomes were similar between LEU and PLA. Results indicate that a 6g daily dose of free leucine supplementation does not improve muscle recovery following lower-limb RE in untrained young adults

Boundary value problems for second order linear difference equations: application to the computation of the inverse of generalized Jacobi matrices

We have named generalized Jacobi matrices to those that are practically tridiagonal, except for the two final entries and the two first entries of its first andits last row respectively. This class of matrices encompasses both standard Jacobiand periodic Jacobi matrices that appear in many contexts in pure and appliedmathematics. Therefore, the study of the inverse of these matrices becomes ofspecific interest. However, explicit formulas for inverses are known only in a fewcases, in particular when the coefficients of the diagonal entries are subjected tosome restrictions.We will show that the inverse of generalized Jacobi matrices can be raisedin terms of the resolution of a boundary value problem associated with a secondorder linear difference equation. In fact, recent advances in the study of lineardifference equations, allow us to compute the solution of this kind of boundaryvalue problems. So, the conditions that ensure the uniqueness of the solution ofthe boundary value problem leads to the invertibility conditions for the matrix,whereas that solutions for suitable problems provide explicitly the entries of theinverse matrix.Peer ReviewedPostprint (author's final draft

Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b

Secretory cells produce diverse cargoes, yet how they regulate concomitant secretory traffic remains insufficiently explored. Rab GTPases control intracellular vesicular transport. To map secretion pathways, we generated a library of lentivirus-expressed dominant-negative Rab mutants and used it in a large-scale screen to identify regulators of hepatic lipoprotein secretion. We identified several candidate pathways, including those mediated by Rab11 and Rab8. Surprisingly, inhibition of Rab1b, the major regulator of transport from the endoplasmic reticulum to the Golgi, differently affected the secretion of the very-low-density lipoprotein components ApoE and ApoB100, despite their final association on mature secreted lipoprotein particles. Since hepatitis C virus (HCV) incorporates ApoE and ApoB100 into its virus particle, we also investigated infectious HCV secretion and show that its regulation by Rab1b mirrors that of ApoB100. These observations reveal differential regulation of hepatocyte secretion by Rab1b and advance our understanding of lipoprotein assembly and lipoprotein and HCV secretion

Bronchial Thermoplasty Global Registry (BTGR) : 2-year results

Funding This study was sponsored by Boston Scientific Corporation, Marlborough, MA, USA.Objectives Bronchial thermoplasty (BT) is a device-based treatment for subjects ≥18 years with severe asthma not well controlled with inhaled corticosteroids and long-acting beta-agonists. The Bronchial Thermoplasty Global Registry (BTGR) collected real-world data on subjects undergoing this procedure. Design The BTGR is an all-comer, prospective, open-label, multicentre study enrolling adult subjects indicated for and treated with BT. Setting Eighteen centres in Spain, Italy, Germany, the UK, the Netherlands, the Czech Republic, South Africa and Australia Participants One hundred fifty-seven subjects aged 18 years and older who were scheduled to undergo BT treatment for asthma. Subjects diagnosed with other medical conditions which, in the investigator's opinion, made them inappropriate for BT treatment were excluded. Primary and secondary outcome measures Baseline characteristics collected included demographics, Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Test (ACT), medication usage, forced expiratory volume in one second and forced vital capacity, medical history, comorbidities and 12-month baseline recall data (severe exacerbations (SE) and healthcare utilisation). SE incidence and healthcare utilisation were summarised at 1 and 2 years post-BT. Results Subjects' baseline characteristics were representative of persons with severe asthma. A comparison of the proportion of subjects experiencing events during the 12 months prior to BT to the 2-year follow-up showed a reduction in SE (90.3% vs 56.1%, p<0.0001), emergency room visits (53.8% vs 25.5%, p<0.0001) and hospitalisations (42.9% vs 23.5 %, p=0.0019). Reductions in asthma maintenance medication dosage were also observed. AQLQ and ACT scores improved from 3.26 and 11.18 at baseline to 4.39 and 15.54 at 2 years, respectively (p<0.0001 for both AQLQ and ACT). Conclusions The BTGR demonstrates sustained improvement in clinical outcomes and reduction in asthma medication usage 2 years after BT in a real-world population. This is consistent with results from other BT randomised controlled trials and registries and further supports improvement in asthma control after BT. Trial registration number NCT02104856